Approval · Notice of Compliance 14822 · 2013
ABRAXANE: Notice of Compliance 14822
Issued October 16, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14822
- Date
- October 16, 2013
- Company
- Celgene IncSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of drug product manufacturing site
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABRAXANE | Not yet assigned | — |
Medicinal ingredients
- PACLITAXEL 100 MG per VIAL